Dermatomyositis

Obinutuzumab in connective tissue diseases after former rituximab-non-response: a case series
Peter Kvacskay, Wolfgang Merkt, Janine Günther, Norbert Blank, Hanns-Martin Lorenz

Annals of the Rheumatic Diseases May 2022, 81 (5) 744-746; DOI: 10.1136/annrheumdis-2021-221756
External validation of EULAR/ACR classification criteria for idiopathic inflammatory myopathies
Queenie Luu, Jessica Day, Alix Hall, Vidya Limaye, Gabor Major

Annals of the Rheumatic Diseases Apr 2022, 81 (4) e59; DOI: 10.1136/annrheumdis-2020-217568
Response to: ‘Immune-mediated necrotizing myopathies and interstitial lung disease are predominant characteristics in anti-Ku positive patients with idiopathic inflammatory myopathies’ by Yang et al
Lionel Spielmann, Benoit Nespola, Alain Meyer

Annals of the Rheumatic Diseases Mar 2022, 81 (3) e49; DOI: 10.1136/annrheumdis-2020-217106
Rheumatic disorders associated with immune checkpoint inhibitors: what about myositis? An analysis of the WHO’s adverse drug reactions database
Thủy Nguyễn, Alexandre Thibault Jacques Maria, Chayma Ladhari, Pascale Palassin, Xavier Quantin, Candice Lesage, Guillaume Taïeb, Xavier Ayrignac, Patricia Rullier, Dominique Hillaire-Buys, Olivier Lambotte, Philippe Guilpain, Jean-Luc Faillie

Annals of the Rheumatic Diseases Feb 2022, 81 (2) e32; DOI: 10.1136/annrheumdis-2020-217018
Familial aggregation and heritability: a nationwide family-based study of idiopathic inflammatory myopathies
Weng Ian Che, Helga Westerlind, Ingrid E Lundberg, Karin Hellgren, Ralf Kuja-Halkola, Marie Holmqvist

Annals of the Rheumatic Diseases Nov 2021, 80 (11) 1461-1466; DOI: 10.1136/annrheumdis-2021-219914
Correspondence on ‘Machine learning algorithms reveal unique gene expression profiles in muscle biopsies from patients with different types of myositis’
Satoshi Takanashi

Annals of the Rheumatic Diseases Dec 2020, annrheumdis-2020-219677; DOI: 10.1136/annrheumdis-2020-219677
Immune response to dermatomyositis-specific autoantigen, transcriptional intermediary factor 1γ can result in experimental myositis
Naoko Okiyama, Yuki Ichimura, Miwako Shobo, Ryota Tanaka, Noriko Kubota, Akimasa Saito, Yosuke Ishitsuka, Rei Watanabe, Yasuhiro Fujisawa, Yoshiyuki Nakamura, Akihiro Murakami, Hisako Kayama, Kiyoshi Takeda, Manabu Fujimoto

Annals of the Rheumatic Diseases Sep 2021, 80 (9) 1201-1208; DOI: 10.1136/annrheumdis-2020-218661
Association of anti-Ro52 autoantibodies with interstitial lung disease in connective tissue diseases
Si Wu, Xiaojun Tang, Liping Wu, Liang-jing Lu, Xuebing Feng

Annals of the Rheumatic Diseases Sep 2021, 80 (9) e151; DOI: 10.1136/annrheumdis-2019-216372
Circulating regulatory T cells were absolutely decreased in dermatomyositis/polymyositis patients and restored by low-dose IL-2
Sheng-Xiao Zhang, Jia Wang, He-Hua Sun, Jia-Qian Zhang, Guang-Ying Liu, Jing Luo, Pei-Feng He, Xiao-Feng Li

Annals of the Rheumatic Diseases Aug 2021, 80 (8) e130; DOI: 10.1136/annrheumdis-2019-216246
Standardisation of myositis-specific antibodies: where are we today?
Michael Mahler, Jean-Baptiste Vulsteke, Xavier Bossuyt, Ellen De Langhe, Minoru Satoh

Annals of the Rheumatic Diseases Aug 2021, 80 (8) e132; DOI: 10.1136/annrheumdis-2019-216003

Main menu

Dermatomyositis

Pages

Log in using your username and password

Main menu

Log in using your username and password

You are here

Dermatomyositis

Pages